|
1
|
Chang ET and Adami HO: The enigmatic
epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol
Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guigay J: Advances in nasopharyngeal
carcinoma. Curr Opin Oncol. 20:264–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Agulnik M and Epstein JB: Nasopharyngeal
carcinoma: current management, future directions and dental
implications. Oral Oncol. 44:617–627. 2008. View Article : Google Scholar
|
|
4
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma BB, Hui EP and Chan AT: Systemic
approach to improving treatment outcome in nasopharyngeal
carcinoma: current and future directions. Cancer Sci. 99:1311–1318.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schnell O, Krebs B, Wagner E, et al:
Expression of integrin alphavbeta3 in gliomas correlates with tumor
grade and is not restricted to tumor vasculature. Brain Pathol.
18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katayama K, Furuki R, Yokoyama H, et al:
Enhanced in vivo gene transfer into the placenta using RGD
fiber-mutant adenovirus vector. Biomaterials. 32:4185–4193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park J, Singha K, Son S, Kim J, Namgung R,
Yun CO and Kim WJ: A review of RGD-functionalized nonviral gene
delivery vectors for cancer therapy. Cancer Gene Ther. 19:741–748.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O’Neill AM, Smith AN, Spangler EA, et al:
Resistance of canine lymphoma cells to adenoviral infection due to
reduced cell surface RGD binding integrins. Cancer Biol Ther.
11:651–658. 2011. View Article : Google Scholar
|
|
10
|
Shiseki M, Nagashima M, Pedeux RM, et al:
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
|
|
11
|
Ythier D, Larrieu D, Brambilla C,
Brambilla E and Pedeux R: The new tumor suppressor genes ING:
genomic structure and status in cancer. Int J Cancer.
123:1483–1490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Palacios A, Moreno A, Oliveira BL, et al:
The dimeric structure and the bivalent recognition of H3K4me3 by
the tumor suppressor ING4 suggests a mechanism for enhanced
targeting of the HBO1 complex to chromatin. J Mol Biol.
396:1117–1127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Martinka M and Li G: Role of ING4 in
human melanoma cell migration, invasion and patient survival.
Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garkavtsev I, Kozin SV, Chernova O, et al:
The candidate tumour suppressor protein ING4 regulates brain tumour
growth and angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Yu L, Wang Y, Zhang Y, Wang Y and
Zhang G: Expression of tumor suppressor gene ING4 in ovarian
carcinoma is correlated with microvessel density. J Cancer Res Clin
Oncol. 138:647–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng ZL, Li FJ, Gao F, Sun DS and Yao L:
Upregulation of miR-650 is correlated with down-regulation of ING4
and progression of hepatocellular carcinoma. J Surg Oncol.
107:105–110. 2013. View Article : Google Scholar
|
|
17
|
Xie Y, Sheng W, Miao J, Xiang J and Yang
J: Enhanced antitumor activity by combining an adenovirus harboring
ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther.
18:176–188. 2011. View Article : Google Scholar :
|
|
18
|
Zhao Y, Su C, Zhai H, Tian Y, Sheng W,
Miao J and Yang J: Synergistic antitumor effect of
adenovirus-mediated hING4 gene therapy and (125)I radiation therapy
on pancreatic cancer. Cancer Lett. 316:211–218. 2012. View Article : Google Scholar
|
|
19
|
Ling C, Xie Y, Zhao D, Zhu Y, Xiang J and
Yang J: Enhanced radiosensitivity of non-small-cell lung cancer
(NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther.
19:697–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Unoki M, Shen JC, Zheng ZM and Harris CC:
Novel splice variants of ING4 and their possible roles in the
regulation of cell growth and motility. J Biol Chem.
281:34677–34686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leslie NR and Foti M: Non-genomic loss of
PTEN function in cancer: not in my genes. Trends Pharmacol Sci.
32:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leslie NR, Yang X, Downes CP and Weijer
CJ: PtdIns(3,4,5) P(3)-dependent and -independent roles for PTEN in
the control of cell migration. Curr Biol. 17:115–125. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Putz U, Howitt J, Doan A, Goh CP, Low LH,
Silke J and Tan SS: The tumor suppressor PTEN is exported in
exosomes and has phosphatase activity in recipient cells. Sci
Signal. 5:ra702012.PubMed/NCBI
|
|
26
|
Hopkins BD, Fine B, Steinbach N, et al: A
secreted PTEN phosphatase that enters cells to alter signaling and
survival. Science. 341:399–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang W, Qin SK, Chen BA and Chen HY:
Experimental study on antitumor effect of arsenic trioxide in
combination with cisplatin or doxorubicin on hepatocellular
carcinoma. World J Gastroenterol. 7:702–705. 2001.
|
|
29
|
Jung YS, Qian Y and Chen X: Examination of
the expanding pathways for the regulation of p21 expression and
activity. Cell Signal. 22:1003–1012. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blain SW: Switching cyclin D-Cdk4 kinase
activity on and off. Cell Cycle. 7:892–898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou C, Li X, Du W, et al: Antitumor
effects of ginkgolic acid in human cancer cell occur via cell cycle
arrest and decrease the Bcl-2/Bax ratio to induce apoptosis.
Chemotherapy. 56:393–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee JS, Jung WK, Jeong MH, Yoon TR and Kim
HK: Sanguinarine induces apoptosis of HT-29 human colon cancer
cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent
pathway. Int J Toxicol. 31:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Church DN and Talbot DC: Survivin in solid
tumors: rationale for development of inhibitors. Curr Oncol Rep.
14:120–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roskoski R Jr: Vascular endothelial growth
factor (VEGF) signaling in tumor progression. Crit Rev Oncol
Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Canavese M and Spaccapelo R: Protective or
pathogenic effects of vascular endothelial growth factor (VEGF) as
potential biomarker in cerebral malaria. Pathog Glob Health.
108:67–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
